Radiotherapy beats anti-hormonal therapy for some breast cancer patients, says study
Endroit courant :
> This Story

Ouverture ou Registre to rate this News Story
Forward Printable StoryPrint Comment




Rad Oncology Homepage

MD Anderson to expand proton therapy center with $159 million project Increases accessibility to higher number of patients

New technique may concentrate radiotherapy dose for minimal tissue damage Utilizes very high energy electrons (VHEEs)

MedAustron delivers first bout of carbon ion therapy on patient Sixth center in the world to offer treatment

Research shows how hurricanes hinder radiotherapy outcomes Treatment transfers and eliminating out-of-network insurance charges could help

Elekta to distribute C-RAD SIGRT technology in North America and Mexico Advances stereotactic radiosurgery and stereotactic body radiotherapy

CMS proposes alternative payment model for radiation oncology Uses prospective, episode-based payments; ensures value-based care

FDA gives RaySearch green light for RayStation 8B platform First treatment planning system to offer machine learning applications

MedAustron to add health IT to proton and carbon ion treatment facilities Orders more than $13 million worth of RaySearch systems

'Nudge' in EHRs cuts imaging in half for palliative radiotherapy, says study Reduces duration of radiotherapy sessions

Mayo Clinic Florida campus to get $233 million proton facility The 140,000-square-foot facility will house a two-gantry proton system

Older patients with low-risk, hormonal
breast cancer may benefit more
from radiotherapy than anti-
hormonal therapy

Radiotherapy beats anti-hormonal therapy for some breast cancer patients, says study

par John R. Fischer , Staff Reporter
Older women with low-risk, hormone-positive breast cancer may be better off with a short dose of radiation instead of anti-hormonal therapy, according to a new study.

Conducted by 21st Century Oncology, the report asserts that radiotherapy may be a better substitute for anti-estrogen pills, which are prone to cause adverse side effects such as hot flashes, weight gain and bone fracture.

Story Continues Below Advertisement


Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.

“They think because it [radiotherapy] is more expensive and doesn't affect survival rates that it's not worth it,” Dr. Frank Vicini, principal investigator at 21st Century Oncology, told HCB News. “But they aren't factoring in the quality-of-life issues associated with anti-hormonal therapy, and those factors are important, too.”

He and physicians from several centers conducted three trials and two meta-analyses using data from 200,000 women, age 70 or older. They determined that low-risk patients who underwent a lumpectomy and chose anti-hormonal therapy experienced only slightly higher survival rates than those treated with radiotherapy.

In addition, the model found that radiation yielded only a slight increase in cost to the healthcare system at $3,809 over the average lifetime. The finding was based on eight survival metrics and cost differentials.

While only 50 percent of patients continue taking daily pills over a five-year period when on hormonal therapy, physicians are more inclined to prescribe it instead of radiotherapy, according to Vicini, who says that patients should consult their physicians about the side effects and requirements of hormone therapy, as well as cost when deciding between it and radiotherapy. He adds that radiotherapy may be a better option for women who want to avoid what can be severe side effects of endocrine therapy.

“The study found that it costs $3,809 more for radiation vs. hormonal therapy over the average patient lifetime,” he said. “But, remember, those added costs are to the healthcare system, not the patient. These patients should also seriously consider whether they'll remember/want to take a daily pill for the next five years.”

Among the institutions that took part in the trials and meta-analyses are the Cleveland Clinic, Harvard, Memorial Sloan Kettering, and the University of Michigan.

The findings were published in the International Journal of Radiation Oncology.

Rad Oncology Homepage

You Must Be Logged In To Post A Comment